Adlai Nortye

Adlai Nortye is a company listed under the stock ticker ANL (US).

Acquisition, funding and merger involving Adlai Nortye.

• Adlai Nortye has filed its IPO. Its stock ticker will be . (posted on October 2 2023).

View the org chart displaying its 17 main executives

Most searched biographies at Adlai Nortye

• Carsten Lu, Chief Executive Officer and Director
• Ping Ji, Director
• Cheguo Cai, Independent Director

Popular executive movements at Adlai Nortye

• Archie Tse has joined the company as Head of Research & Development  (posted on March 31 2024).

Create your alert
to follow the executive moves at Adlai Nortye.

Adlai Nortye has 2,288 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on May 13 2024).
• Aardvark Therapeutics has just announced a $85 Million fundraising (posted on May 12 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by Adlai Nortye

• Media
• Media

Social media about Adlai Nortye

• Adlai Nortye on Wikipedia, Google News & Yahoo Finance
• Adlai Nortye on LinkedIn, Twitter & YouTube

Contact by email its executives including Carsten Lu

Call Adlai Nortye at +86 571 ...

View the org chart

Register to receive your alert

Report an error